Understand the source comparison
VIP Alternatives 2026 Best: Metabolic and Immune Peptides Comparison
Tirzepatide Dual GLP-1/GIP agonist GLP-1R, GIPR ~5 days Metabolic research, insulin sensitivity studies Strongest metabolic efficacy data among dual agonists; 20.9% mean weight reduction in SURMOUNT-1 trial Survodutide Dual GLP-1/glucagon agonist GLP-1R, GCGR
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide
- Dual GLP-1/GIP agonist
- GLP-1R, GIPR
- ~5 days
- Metabolic research, insulin sensitivity studies
- Strongest metabolic efficacy data among dual agonists; 20.9% mean weight reduction in SURMOUNT-1 trial
- Survodutide
- Dual GLP-1/glucagon agonist
- GLP-1R, GCGR
- ~7 days
- Thermogenesis research, hepatic metabolism
- Additive fat oxidation beyond GLP-1 monotherapy; requires careful titration due to glucagon effects
- Mazdutide
- ~6 days
- Energy expenditure studies
- Higher glucagon affinity than survodutide; stronger thermogenic signal but increased GI side effects
- Cerebrolysin
- Neurotrophic peptide mixture
- TrkB, BDNF pathways
- 2–4 hours
- Neuroprotection, synaptic plasticity
- Mixed peptide preparation; broader mechanism but less receptor specificity than single compounds
- Dihexa
- BDNF mimetic
- TrkB
- 4–6 hours
- Cognitive enhancement, leptin sensitivity
- Higher oral bioavailability than cerebrolysin; cleaner BDNF pathway activation
- MK-677
- Ghrelin receptor agonist
- GHSR1a
- 24 hours
- GH pulse research, IGF-1 studies
- Maintains efficacy across months; preserves natural GH rhythm unlike exogenous GH
- Tesofensine
- Triple monoamine reuptake inhibitor
- DAT, NET, SERT
- ~8 days
- Appetite regulation, noradrenergic research
- Potent appetite suppression via norepinephrine/dopamine; not a peptide but often grouped with metabolic agents
- Thymalin
- Thymus-derived peptide
- Immune cell receptors
- 6–12 hours
- Immune modulation, T-cell function
- Primary immune application; metabolic effects secondary to improved immune-endocrine crosstalk